Ocugen says OCU410 gene therapy enters Phase 3 trials for geographic atrophy

Ocugen said OCU410 has entered Phase 3 trials for geographic atrophy, advancing its gene therapy program into late-stage testing. The candidate is being developed as a one-time treatment for an advanced form of dry age-related macular degeneration.

Detected & updated continuously · Source: Nebula